Transcelerate Biopharma Inc., a nonprofit established by 10 of the industry's largest pharmas in 2012 – and has doubled its membership since then – is charged with the task of reducing redundancy and speeding drug development for its member drug companies. (See BioWorld Today, Sept. 26, 2012.)
San Francisco and San Diego may have a friendly rivalry for the top area of California for biotechs, but when you add them together, the combination is a force to be reckoned with.
The American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC), are teaming up to put on the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics scheduled to kick off on Thursday.
Antibody-drug conjugates (ADCs) may have fallen behind immunotherapy in the oncology-hype department, but plenty of companies are pressing forward with their ADC drugs. Last week, there was an entire conference – the 2015 World ADC Summit – held in San Diego dedicated to the discovery, development and manufacturing of ADCs.
Covalent Data Inc. is looking to become a one-stop shop for drug companies, investment banks and venture capitalists to discover products available for license and company formation while helping academics get across the valley of death.
Smokers have plenty of options to quit, but many restart because of chronic "smoker's cough" caused by mucus buildup in the lungs that forms after they stop smoking.
Smokers have plenty of options to quit, but many restart because of chronic "smoker's cough" caused by mucus buildup in the lungs that forms after they stop smoking.
When you compare third quarter investments in private U.S companies to the rest of 2015, it doesn't look pretty. Just 39 companies tracked by BioWorld Snapshots garnered the attention of venture capitalists in the third quarter compared to 53 in the first quarter and 50 in the second quarter.
Earlier this month, Raptor Pharmaceutical Corp.'s RP103 (cysteamine bitartrate delayed-release) failed a phase IIb trial in pediatric nonalcoholic steatohepatitis (NASH), but the letdown hasn't dampened other companies' enthusiasm for the lucrative NASH market. Good thing, considering there are nearly 90 trials in NASH patients planned or being run by 17 biopharmas and dozens of research institutions, according to Cortellis Clinical Trials Intelligence.
